{"id":3844,"date":"2021-07-28T12:27:07","date_gmt":"2021-07-28T12:27:07","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3844"},"modified":"2021-07-28T12:48:35","modified_gmt":"2021-07-28T12:48:35","slug":"enyo-pharma-annonce-des-resultats-positifs-pour-vonafexor-eyp001-dans-letude-clinique-de-phase-2a-livify-chez-des-patients-nash-f2-f3-apres-12-semaines-de-traitement","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-des-resultats-positifs-pour-vonafexor-eyp001-dans-letude-clinique-de-phase-2a-livify-chez-des-patients-nash-f2-f3-apres-12-semaines-de-traitement\/","title":{"rendered":"ENYO Pharma Annonce des Resultats Positifs pour Vonafexor (EYP001) dans l\u2019Etude Clinique de Phase 2a LIVIFY chez des Patients NASH (F2-F3) apr\u00e8s 12 Semaines de Traitement"},"content":{"rendered":"<p>Lyon, France. Le 28 Juillet 2021 &#8211; ENYO Pharma, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui que Vonafexor a atteint les crit\u00e8res d&#8217;\u00e9valuation principaux et secondaires de l&#8217;\u00e9tude clinique LIVIFY men\u00e9e chez des patients atteints de st\u00e9ato-h\u00e9patite non alcoolique (NASH).<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2021\/07\/20210728-PR-ENYO-on-LIVIFY-study-in-NASH-Final-v1.3-FR.pdf\" target=\"_blank\" rel=\"noopener\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, France. Le 28 Juillet 2021 &#8211; ENYO Pharma, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui que Vonafexor a atteint les crit\u00e8res d&#8217;\u00e9valuation principaux et secondaires de l&#8217;\u00e9tude clinique LIVIFY men\u00e9e chez des patients atteints de st\u00e9ato-h\u00e9patite non alcoolique (NASH).<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-des-resultats-positifs-pour-vonafexor-eyp001-dans-letude-clinique-de-phase-2a-livify-chez-des-patients-nash-f2-f3-apres-12-semaines-de-traitement\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3844","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, France. Le 28 Juillet 2021 &#8211; ENYO Pharma, une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui que Vonafexor a atteint les crit\u00e8res d&#8217;\u00e9valuation principaux et secondaires de l&#8217;\u00e9tude clinique LIVIFY men\u00e9e chez des patients atteints de st\u00e9ato-h\u00e9patite non alcoolique (NASH).Lire la suite&nbsp;&raquo;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3844"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3844\/revisions"}],"predecessor-version":[{"id":3846,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3844\/revisions\/3846"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}